Provided by Tiger Trade Technology Pte. Ltd.

SBP GROUP

5.710
+0.1602.88%
Volume:91.38M
Turnover:522.19M
Market Cap:106.68B
PE:37.62
High:5.800
Open:5.485
Low:5.485
Close:5.550
52wk High:8.335
52wk Low:4.136
Shares:18.68B
HK Float Shares:18.68B
Volume Ratio:1.54
T/O Rate:0.49%
Dividend:0.12
Dividend Rate:2.15%
EPS(LYR):0.152
ROE:14.07%
ROA:7.51%
PB:2.80
PE(LYR):37.62
PS:2.71

Loading ...

Sino Biopharmaceutical Stock Rises 2.9% in Hong Kong

Dow Jones
·
Yesterday

SBP Group Shares Surge Over 4% Intraday; Citi Maintains "Buy" Rating

Deep News
·
Yesterday

Sino Biopharmaceutical Jumps Over 4% as Citi Highlights STADA Partnership to Share Licensing Drug Profits Through Production Supply

Stock News
·
Yesterday

Movement Alert|SBP GROUP Rises 3.33% in Regular Trading, STADA Biosimilar Partnership Continues to Drive Momentum

Market Focus
·
Yesterday

Citi: Sino Biopharmaceutical and STADA Form Biosimilar Strategic Partnership, "Buy" Rating Maintained

Stock News
·
Sep 29

Sino Biopharm Unit CTTQ Presents Phase 3 APEX-Breast01 Data for Tqb2102 in HER2-Low Breast Cancer at ESMO 2026

Reuters
·
Sep 29

Sino Biopharmaceutical Jumps Nearly 4% as Subsidiary Strikes Strategic Biosimilar Deal with STADA, Securing Up to EUR53 Million in Upfront Payment

Stock News
·
Sep 29

Movement Alert|SBP GROUP Rises 3.18% in Regular Trading, Subsidiary Partners with STADA on Biosimilar Strategic Collaboration

Market Focus
·
Sep 29

Sino Biopharma Unit Grants STADA Commercialization License for Pembrolizumab Biosimilar

MT Newswires Live
·
Sep 28

SBP Group and Germany’s STADA Sign €53 Million Biosimilar Commercialisation Agreement for EU, UK and CIS

Bulletin Express
·
Sep 28

Sino Biopharmaceutical - Stada to Hold Marketing Authorizations and Sales Rights in Licensed Territory, Options for US and GCC

THOMSON REUTERS
·
Sep 28

Sino Biopharmaceutical - Enter into Strategic Biosimilars Partnership with Stada

THOMSON REUTERS
·
Sep 28

Sino Biopharmaceutical - Cttq Grants Stada Exclusive License for Pembrolizumab Biosimilar in EU, Switzerland, UK, CIS

THOMSON REUTERS
·
Sep 28

Sino Biopharmaceutical Stock Slides 1.3% in Hong Kong, Underperforms Competitors

Dow Jones
·
Sep 28

SBP GROUP Releases 2026 Interim Report Online and Opens Printed-Copy Requests for Non-Registered Shareholders

Bulletin Express
·
Sep 24

SBP Group Publishes 2026 Interim Report Online and Seeks Wider Adoption of E-Communication

Bulletin Express
·
Sep 24

Sino Biopharmaceutical Stock Slips 1.8% in Hong Kong

Dow Jones
·
Sep 24

Sino Biopharmaceutical Stock Slips 1.4% in Hong Kong, Underperforms Competitors

Dow Jones
·
Sep 22

Market Chatter: US Considers Rules Allowing American Investment in Chinese Drugs

MT Newswires Live
·
Sep 21

Hong Kong Equities Close Higher | Hang Seng Index Regains 25,000 Mark, Innovative Drug Shares Rally Broadly, SBP Group Tops Blue-Chip Gainers

Stock News
·
Sep 21